PMID- 23807645
OWN - NLM
STAT- MEDLINE
DCOM- 20150608
LR  - 20210716
IS  - 1724-6059 (Electronic)
IS  - 1121-8428 (Linking)
VI  - 26
IP  - 6
DP  - 2013 Nov-Dec
TI  - Diabetic nephropathy: new approaches for improving glycemic control and reducing 
      risk.
PG  - 975-85
LID - 10.5301/jn.5000281 [doi]
AB  - Nephropathy is a common consequence of diabetes, with a high prevalence in 
      patients with type 1 (15%-25%) and type 2 diabetes mellitus (T2DM; 30%-40%). 
      Nephropathy is associated with a poor prognosis and high economic burden. The 
      risk of developing nephropathy increases with the duration of diabetes, and early 
      diagnosis and treatment of risk factors for nephropathy (e.g., tight control of 
      glycemia and hypertension) can reduce the development and progression of diabetic 
      nephropathy. Advances in our understanding of the mechanisms of renal 
      complications associated with diabetes and the etiology of nephropathy have 
      identified additional risk factors for nephropathy, and novel therapeutic options 
      are being explored. This review discusses the pathophysiology of diabetic 
      nephropathy and common risk factors. Furthermore, we discuss emerging treatments 
      for T2DM that could potentially slow or prevent the progression of diabetic 
      nephropathy. The use of incretin-based therapies, such as the dipeptidyl 
      peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) analogs, is 
      growing in patients with T2DM, due to their efficacy and tolerability profiles. 
      As renal safety is a key factor when choosing treatment options to manage 
      patients with T2DM, drugs that are suitable for use in patients with varying 
      degrees of renal impairment without a requirement for dose adjustment, such as 
      the DPP-4 inhibitor linagliptin, are of particular use. The ongoing advances in 
      T2DM therapy may allow optimization of glycemic control in a wide range of 
      patients, thereby helping to reduce the increasing morbidity and mortality 
      associated with diabetic nephropathy.
FAU - Schernthaner, Guntram
AU  - Schernthaner G
AD  - Department of Medicine I, Rudolfstiftung Hospital, Vienna - Austria.
FAU - Schernthaner, Gerit Holger
AU  - Schernthaner GH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130614
PL  - Italy
TA  - J Nephrol
JT  - Journal of nephrology
JID - 9012268
RN  - 0 (Amides)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Endothelins)
RN  - 0 (Fumarates)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 0 (Purines)
RN  - 0 (Quinazolines)
RN  - 3X29ZEJ4R2 (Linagliptin)
RN  - 502FWN4Q32 (aliskiren)
RN  - 6SMK8R7TGJ (Oleanolic Acid)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - CEG1Q6OGU1 (bardoxolone methyl)
RN  - EC 3.4.23.15 (Renin)
SB  - IM
CIN - J Nephrol. 2014 Jun;27(3):349. PMID: 24800907
MH  - Amides/therapeutic use
MH  - Antihypertensive Agents/therapeutic use
MH  - Cost of Illness
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/prevention & control
MH  - Diabetic Nephropathies/*drug therapy/etiology/prevention & control
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Endothelins/antagonists & inhibitors
MH  - Fumarates/therapeutic use
MH  - Glucagon-Like Peptide 1/therapeutic use
MH  - Humans
MH  - Hyperglycemia/*drug therapy
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Incretins/metabolism
MH  - Linagliptin
MH  - Oleanolic Acid/analogs & derivatives/therapeutic use
MH  - Purines/therapeutic use
MH  - Quinazolines/therapeutic use
MH  - Renin/antagonists & inhibitors
MH  - Risk Factors
MH  - Risk Reduction Behavior
EDAT- 2013/06/29 06:00
MHDA- 2015/06/09 06:00
CRDT- 2013/06/29 06:00
PHST- 2013/03/11 00:00 [accepted]
PHST- 2013/06/29 06:00 [entrez]
PHST- 2013/06/29 06:00 [pubmed]
PHST- 2015/06/09 06:00 [medline]
AID - 25439FCA-1484-4031-9590-1FE8AF67352A [pii]
AID - 10.5301/jn.5000281 [doi]
PST - ppublish
SO  - J Nephrol. 2013 Nov-Dec;26(6):975-85. doi: 10.5301/jn.5000281. Epub 2013 Jun 14.